BioSpace News Archive

Paradigm today announced the commercial release of a substantially improved next generation sequencing (NGS) panel for patients with late stage and aggressive cancer.

BIOTECanada is pleased to announce the 2018 winners of the Gold Leaf Awards which annually highlight innovation and entrepreneurship within the Canadian biotechnology industry.

A new PSA released by the Association for Frontotemporal Degeneration (AFTD) in partnership with Discovery highlights the challenges faced by families in the wake of a young-onset dementia diagnosis.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today provided an update on advancements to its pipeline programs.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it will redeem $125 million aggregate principal amount of its outstanding 7.50% Senior Notes due 2021, CUSIP Nos. 92912EAA1, C96715AA2 (the “Notes”) on Oct. 26, 2018.

The Medicrea Group announced today that the Company is attending the NASS 2018 meeting taking place in Los Angeles, California, from September 26th to 28th, where UNiD™ LAB biomedical engineers will showcase the most recent developments of the Company’s UNiD™ ASI technology.

The Biologics License Application for SB5 was based on a 52-week Phase 3 study comparing SB5 to the adalimumab reference product

Brammer Bio announces that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.

Americans depend on the U.S. Food and Drug Administration to help ensure that the foods they buy and consume are safe. When we learn that potentially dangerous food products may be available in the U.S. marketplace, we must move quickly and efficiently to remove these food products from the market.

Candela Corporation, a leading global manufacturer of energy-based devices, announces it will be partnering with the Vascular Birthmarks Foundation (VBF) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related skin conditions as a kickoff to the VBF 18th Annual Conference.